JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

Search

Relay Therapeutics Inc

Fechado

SetorSaúde

3.53 -3.29

Visão Geral

Variação de preço das ações

24h

Atual

Mín

3.53

Máximo

3.73

Indicadores-chave

By Trading Economics

Rendimento

-1.1M

-77M

Vendas

7.7M

7.7M

Margem de lucro

-1,003.581

Funcionários

259

EBITDA

-1.2M

-85M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+239.18% upside

Dividendos

By Dow Jones

Próximos Ganhos

7 de ago. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

80M

634M

Abertura anterior

6.82

Fecho anterior

3.53

Sentimento de Notícias

By Acuity

50%

50%

176 / 374 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Strong Bearish Evidence

Relay Therapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

5 de ago. de 2025, 23:11 UTC

Ganhos

Australia's REA Hikes Dividend as Annual Profit Rises 23% -- Update

5 de ago. de 2025, 22:45 UTC

Ganhos

Australia's REA Hikes Dividend as Annual Profit Rises 23%

5 de ago. de 2025, 22:39 UTC

Ganhos

Great-West Lifeco Logs Lower 2Q Profit

5 de ago. de 2025, 21:32 UTC

Ganhos

Coupang Posts Higher 2Q Sales Due to Customer Growth

6 de ago. de 2025, 00:00 UTC

Aquisições, Fusões, Aquisições de Empresas

NFL to Take 10% Stake in Disney's ESPN -- WSJ

6 de ago. de 2025, 00:00 UTC

Aquisições, Fusões, Aquisições de Empresas

The NFL Is Taking a 10% Stake in Disney's ESPN -- WSJ

6 de ago. de 2025, 00:00 UTC

Aquisições, Fusões, Aquisições de Empresas

Disney to Take Control of NFL Network as Part of Agreement -- WSJ

6 de ago. de 2025, 00:00 UTC

Aquisições, Fusões, Aquisições de Empresas

Disney, NFL Strike Wide-Reaching Media-Asset Deal -- WSJ

5 de ago. de 2025, 23:48 UTC

Conversa de Mercado

Nikkei May Decline Amid U.S. Economic Uncertainty -- Market Talk

5 de ago. de 2025, 23:40 UTC

Conversa de Mercado

Gold Edges Higher, Supported by Fed Rate-Cut Hopes -- Market Talk

5 de ago. de 2025, 23:19 UTC

Conversa de Mercado

Lindian Deal With Iluka Demonstrates Kangankunde Project Appeal -- Market Talk

5 de ago. de 2025, 23:03 UTC

Conversa de Mercado
Ganhos

Advanced Micro Devices' Data-Center Story Seen as Promising -- Market Talk

5 de ago. de 2025, 22:22 UTC

Ganhos

REA: Expectation of More Interest-Rate Cuts Likely to Support Buyer Demand>REA.AU

5 de ago. de 2025, 22:21 UTC

Ganhos

REA Expects FY26 Listing Volumes Broadly Flat on FY25>REA.AU

5 de ago. de 2025, 22:20 UTC

Ganhos

REA Expects September-Quarter Listings to Be Down on Year>REA.AU

5 de ago. de 2025, 22:18 UTC

Ganhos

REA July 2025 New Residential Listings Down 8% on Year>REA.AU

5 de ago. de 2025, 22:17 UTC

Ganhos

REA FY25 Australian Residential Listings Up 1% on Year>REA.AU

5 de ago. de 2025, 22:17 UTC

Ganhos

REA FY25 India Revenue A$129M Vs. A$103M>REA.AU

5 de ago. de 2025, 22:16 UTC

Ganhos

REA FY25 Core Australia Revenue A$1.54B Vs. A$1.35B>REA.AU

5 de ago. de 2025, 22:16 UTC

Ganhos

REA FY25 Core Operations Net Profit A$564.4M Vs. A$460.5M>REA.AU

5 de ago. de 2025, 22:15 UTC

Ganhos

REA Group FY25 Ebitda A$969.2M Vs. A$824.8M>REA.AU

5 de ago. de 2025, 22:13 UTC

Ganhos

REA Group Raises Dividend to A$1.38 Vs. A$1.02 >REA.AU

5 de ago. de 2025, 22:13 UTC

Ganhos

REA Group FY25 Rev A$1.67B Vs. A$1.45B >REA.AU

5 de ago. de 2025, 22:12 UTC

Ganhos

REA FY25 Core Operations Net Profit A$564.4M Vs, A$460.5M>REA.AU

5 de ago. de 2025, 22:12 UTC

Ganhos

REA Group FY25 Net A$677.9M Vs. Net A$302.8M >REA.AU

5 de ago. de 2025, 21:58 UTC

Ganhos

Novo Nordisk's Earnings Come After a Dramatic Guidance Cut. What to Look for Now. -- Barrons.com

5 de ago. de 2025, 21:30 UTC

Ganhos

AMD Gives a Strong Outlook. Why the Stock Is Falling. -- Barrons.com

5 de ago. de 2025, 21:26 UTC

Ganhos

AMD CEO Expects Embedded Segment to Return to Sequential Growth in Back Half of 2025

5 de ago. de 2025, 21:23 UTC

Ganhos

AMD CEO Sees Strong Customer Interest in MI400 Series for Large-Scale Deployments

5 de ago. de 2025, 21:17 UTC

Ganhos

AMD Expects Steep Production Ramp for MI350 Series in Back Half of Year, CEO Says

Comparação entre Pares

Variação de preço

Relay Therapeutics Inc Previsão

Preço-alvo

By TipRanks

239.18% parte superior

Previsão para 12 meses

Média 12.38 USD  239.18%

Máximo 17 USD

Mínimo 4 USD

Com base em 9 analistas de Wall Street que oferecem metas de preço de 12 meses para Relay Therapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

9 ratings

8

Comprar

1

Manter

0

Vender

Pontuação Técnica

By Trading Central

2.88 / 3.285Suporte e Resistência

Curto Prazo

Strong Bearish Evidence

Médio Prazo

Strong Bullish Evidence

Longo Prazo

No Evidence

Sentimento

By Acuity

176 / 374 Ranking em Saúde

Sentimento de Notícias

Neutral

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Relay Therapeutics Inc

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.